Sanuwave Completes Modular PMA For Diabetic Foot Ulcer Treatment
This article was originally published in The Gray Sheet
Executive Summary
Sanuwave Health completed a modular PMA application for its dermaPACE diabetic foot ulcer treatment with the submission of pivotal trial data, announced July 6.
You may also be interested in...
Sanuwave On Track To Submit dermaPACE PMA By June 30
Sanuwave Health says it is on track to wrap up a PMA submission by the end of June for its dermaPACE wound care device, which treats chronic diabetic foot ulcers with high-energy acoustic pressure waves.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.